ALEXITOL SODIUM - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

ultomiris ravulizumab rch 10 mg/ml concentrated solution for intravenous infusion vial

alexion pharmaceuticals australasia pty ltd - ravulizumab, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: monobasic sodium phosphate; dibasic sodium phosphate; sodium chloride; polysorbate 80; water for injections - ultomiris is indicated:,? for the treatment of patients with paroxysmal nocturnal haemoglobinuria (pnh),? for the treatment of patients with atypical haemolytic uraemic syndrome (ahus),? as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti-acetylcholine receptor (achr) antibody-positive.,? for the treatment of adult patients with neuromyelitis optica spectrum disorder (nmosd) who are anti-aquaporin 4 (aqp4) antibody-positive.,ultomiris is not intended for the acute treatment of a nmosd relapse.

United States - English - NLM (National Library of Medicine)

hlal rdna construct in sbc lal-c chickens- hlal rdna construct in sbc lal-c chicken not applicable

alexion pharmaceuticals, inc. - hlal rdna construct in sbc lal-c chicken (unii: mg6au4c2hb) (hlal rdna construct in sbc lal-c chicken - unii:mg6au4c2hb) - hlal rdna construct in sbc lal-c chicken 1 [arb'u] in 1 [arb'u] - the sbc lal-c lineage must be housed in only those alexion pharmaceutical, inc. facilities specified in the approved application.